查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
活性藥物成分市場 - 全球市場規模、佔有率、趨勢分析、機遇和預測報告，2019-2029
市場調查報告書
商品編碼
1310387

活性藥物成分市場 - 全球市場規模、佔有率、趨勢分析、機遇和預測報告，2019-2029

Active Pharmaceutical Ingredients Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By API ; By Manufacturer ; By Type of Drug ; By Therapeutic Area ; By Potency ; Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到 2029 年，全球活性藥物成分 (API) 市場有望達到 3250 億美元

由於全球慢性病的增加、學名藥生產的擴大以及藥品製造技術的進步，對具有成本效益的藥物的需求不斷增加，全球活性藥物成分（API）市場正在蓬勃發展。

領先的戰略諮詢和市場研究公司 BlueWeave Consulting 最近估計，2022 年全球活性藥物成分 (API) 市場價值將達到 2324 億美元。 BlueWeave 預測，2023-2029 年預測期內，全球活性藥物成分 (API) 市場規模將以 5.69% 的複合年複合成長率成長，到 2029 年達到 3246.7 億美元。心血管疾病、癌症和糖尿病等慢性疾病的全球負擔日益增加，推動了對有效且具有成本效益的治療方案的需求。 API 構成了藥物的支柱，隨著治療干涉需求的成長，開發和生產這些藥物對 API 的需求也會增加。此外，製藥公司大力投資研發活動，以推出創新藥物和治療方法。對研發的更多關注將進一步增加對活性藥物成分的需求，活性藥物成分是藥物開發的關鍵組成部分。由於技術進步和藥物發現投資的增加，全球活性藥物成分（API）市場預計在未來幾年將出現顯著成長。

該報告的詳細分析提供了有關全球活性藥物成分（API）市場的成長潛力、未來趨勢和統計數據的資訊。它還重點關注推動市場總規模預測的因素。該報告致力於為決策者提供全球活性藥物成分（API）市場的最新技術趨勢以及行業見解，以做出明智的戰略決策。它還分析了市場的成長促進因素、挑戰和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球原料藥（API）市場洞察

  • 行業價值鏈分析
  • DROC分析
    • 成長促進因素
      • 學名藥需求不斷成長
      • 慢性病患病率上升
      • 更加注重新 API 的研發
    • 抑制因素
      • 嚴格的監管要求
      • 價格波動
    • 機會
      • 新興市場需求不斷成長
      • 新技術開發
    • 任務
      • 監管挑戰
      • 與學名藥的競爭
  • 技術進步/最新發展
  • 監管框架
  • 波特五力分析

第4章 全球活性藥物成分（API）市場概述

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過API
      • 合成原料藥
      • 生物原料藥
    • 按製造商
      • 俘虜製造者
      • 經銷商製造商
    • 按藥物類型
      • 品牌/創新藥
      • 學名藥
    • 按治療領域
      • 心血管系統
      • 中樞神經系統（CNS）
      • 呼吸系統
      • 腫瘤學
      • 消化系統
      • 其他
    • 按功效
      • 舊版 API
      • HPAPI
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第5章 北美活性藥物成分（API）市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過API
    • 按製造商
    • 按藥物類型
    • 按治療領域
    • 按功效
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲活性藥物成分（API）市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過API
    • 按製造商
    • 按藥物類型
    • 按治療領域
    • 按功效
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第7章 亞太原料藥（API）市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過API
    • 按製造商
    • 按藥物類型
    • 按治療領域
    • 按功效
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳大利亞和紐西蘭
      • 印度尼西亞
      • 馬來西亞
      • 新加坡
      • 越南
      • 亞太地區其他地區

第8章 拉丁美洲活性藥物成分 (API) 市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 拉丁美洲其他地區

第9章 中東和非洲原料藥（API）市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過API
    • 按製造商
    • 按藥物類型
    • 按治療領域
    • 按功效
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • MEA 的其餘部分

第10章 競爭格局

  • 主要公司及其產品列表
  • 2022 年全球活性藥物成分 (API) 市場佔有率分析
  • 通過運行參數進行競爭基準測試
  • 主要戰略發展（合併、收購、合作夥伴關係等）

第11章COVID-19 對活性藥物成分市場的影響

第12章公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人才、主要競爭、聯繫地址、戰略展望、SWOT分析）

  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Novartis International AG
  • Mylan NV
  • Aurobindo Pharma Ltd
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim GmbH
  • Dr. Reddy's Laboratories Ltd
  • Merck & Co., Inc.
  • Lonza Group Ltd
  • Bristol-Myers Squibb
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Lupin Limited
  • Cipla Ltd
  • Other Prominent Players

第13章關鍵戰略建議

第14章調查方法

  • 定性研究
    • 初級和次級研究
  • 定量研究
  • 市場細分和數據三角測量
    • 二次調查
    • 初步調查
  • 主要調查受訪者的地區分佈
  • 假設和限制
簡介目錄
Product Code: BWC19271

Global Active Pharmaceutical Ingredients (API) Market Size Booming to Touch USD 325 Billion by 2029.

Global active pharmaceutical ingredients (API) market is flourishing due to a high demand for cost-effective medicines driven by the increasing prevalence of chronic diseases across the world, expansion of generic drug manufacturing, and advancements in drug manufacturing technology.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global active pharmaceutical ingredients (API) market size was worth USD 232.4 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global active pharmaceutical ingredients (API) market size to grow at a CAGR of 5.69% reaching a value of USD 324.67 billion by 2029. The rising global burden of chronic diseases, such as cardiovascular diseases, cancer, and diabetes, is driving the demand for effective and cost-efficient treatment options. APIs form the backbone of pharmaceutical drugs, and the growing need for therapeutic interventions will lead to an increased demand for APIs to develop and manufacture these medications. Moreover, pharmaceutical companies are investing heavily in R&D activities to introduce innovative drugs and therapies. The increasing focus on R&D will further drive the demand for APIs as they are the key components in drug development. With advancements in technology and increasing investments in novel drug discoveries, the global active pharmaceutical ingredients (API) market is expected to witness substantial growth in the coming years.

Increasing demand for generic drugs:

Generic drugs are cost-effective alternatives to branded drugs, offering the same therapeutic benefits at lower prices. This affordability makes them accessible to a larger population, driving their demand and subsequently boosting the API market. As patents expire for branded drugs, generic drug manufacturers can enter the market with their versions, utilizing APIs to produce these cost-effective alternatives. This creates opportunities for API manufacturers to supply the necessary ingredients for generic drug production. For example, when the patent for a popular branded drug expires, multiple generic manufacturers can develop their versions using the same API. This leads to increased competition, resulting in lower prices and wider availability of the drug. As a result, patients and healthcare providers can choose more affordable options, reducing healthcare costs, and increasing accessibility. A study by the World Health Organization (WHO) found that generic drugs can save up to 80% of the cost of branded drugs. The WHO also estimates that generic drugs could save the global healthcare system USD 200 billion per year. As a result, governments and healthcare systems worldwide are actively promoting the use of generic drugs to reduce healthcare expenditures. In some cases, regulations may even mandate the prescription of generic drugs whenever possible. This policy support further drives the demand for generic drugs and, consequently, the growth of global API market. The growing demand for generic drugs is also fueled by the increasing prevalence of chronic diseases globally. As the population ages and chronic conditions become more prevalent, the need for cost-effective treatment options rises. Generic drugs, enabled by APIs, play a vital role in meeting the increasing demand and providing affordable healthcare solutions.

Segmental Information:

Global Active Pharmaceutical Ingredients (API) Market - By Therapeutic Area:

Based on therapeutic area, the global active pharmaceutical ingredients (API) market is segmented into the cardiovascular system, central nervous system, respiratory system, oncology, gastrointestinal system, and others. The cardiovascular system segment held the largest market share in the global active pharmaceutical ingredients (API) market, due to the prominence of cardiovascular drugs and therapies. Cardiovascular diseases, including heart diseases, stroke, and hypertension, are prevalent worldwide and remain one of the leading causes of morbidity and mortality. The increasing incidence of cardiovascular disorders, coupled with the aging population and lifestyle changes, drives the demand for pharmaceutical interventions in this therapeutic area. As a result, there is a substantial need for API-based medications targeting the cardiovascular system. The cardiovascular API market benefits from the continuous development of innovative treatments and therapies. Furthermore, cardiovascular drugs often require long-term treatment, contributing to a sustained demand for APIs in the cardiovascular therapeutic area. Patients with cardiovascular conditions typically require medications that help regulate blood pressure, manage cholesterol levels, and prevent blood clots. As these drugs are frequently prescribed and used over extended periods, the demand for cardiovascular APIs remains high. Governments and healthcare organizations worldwide also prioritize cardiovascular health due to its substantial economic and healthcare burden. Public health initiatives and awareness campaigns further drive the demand for cardiovascular medications, boosting the market growth for cardiovascular APIs.

Impact of COVID-19 on Global Active Pharmaceutical Ingredients Market:

The COVID-19 pandemic had a mixed impact on the global active pharmaceutical ingredients (API) market. While the demand for certain APIs surged due to the production of drugs and vaccines to combat the virus, other segments experienced disruptions. Supply chain disruptions, restrictions on trade, and raw material shortages impacted API manufacturing and distribution. The increased focus on healthcare preparedness and vaccine development during the pandemic drove the demand for APIs. The pandemic also highlighted the importance of domestic API production, leading to efforts by governments to strengthen local manufacturing capabilities. Overall, the COVID-19 pandemic reshaped the API market dynamics, emphasizing the need for resilient supply chains and domestic manufacturing capacities.

Competitive Landscape:

The global active pharmaceutical ingredients (API) market is fragmented, with many players serving the market. The key players dominating the global active pharmaceutical ingredients (API) market include Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis International AG, Mylan N.V., Aurobindo Pharma Ltd, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Dr Reddy's Laboratories Ltd, Merck & Co., Inc., Lonza Group Ltd, Bristol-Myers Squibb, GlaxoSmithKline plc, AbbVie Inc., Lupin Limited, and Cipla Ltd. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisition to expand their customer reach and gain a competitive edge in the overall market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Active Pharmaceutical Ingredients (API) Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Active Pharmaceutical Ingredients (API) Market along with industry insights to help decision-makers make sound strategic decisions. The report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Active Pharmaceutical Ingredients (API) Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing demand for generic drugs
      • 3.2.1.2. Rising prevalence of chronic diseases
      • 3.2.1.3. Growing focus on research and development of new APIs
    • 3.2.2. Restrains
      • 3.2.2.1. Stringent regulatory requirements
      • 3.2.2.2. Price volatility
    • 3.2.3. Opportunities
      • 3.2.3.1. Growing demand from emerging markets
      • 3.2.3.2. Development of new technologies
    • 3.2.4. Challenges
      • 3.2.4.1. Regulatory challenges
      • 3.2.4.2. Competition from generics
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Active Pharmaceutical Ingredients (API) Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By API
      • 4.2.1.1. Synthetic API
      • 4.2.1.2. Biological API
    • 4.2.2. By Manufacturer
      • 4.2.2.1. Captive Manufacturers
      • 4.2.2.2. Merchant Manufacturers
    • 4.2.3. By Type of Drug
      • 4.2.3.1. Branded/Innovator Drugs
      • 4.2.3.2. Generic Drugs
    • 4.2.4. By Therapeutic Area
      • 4.2.4.1. Cardiovascular System
      • 4.2.4.2. Central Nervous System (CNS)
      • 4.2.4.3. Respiratory System
      • 4.2.4.4. Oncology
      • 4.2.4.5. Gastrointestinal System
      • 4.2.4.6. Others
    • 4.2.5. By Potency
      • 4.2.5.1. Traditional API
      • 4.2.5.2. HPAPI
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia Pacific (APAC)
      • 4.2.6.4. Latin America (LATAM)
      • 4.2.6.5. Middle East and Africa (MEA)

5. North America Active Pharmaceutical Ingredients (API) Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By API
    • 5.2.2. By Manufacturer
    • 5.2.3. By Type of Drug
    • 5.2.4. By Therapeutic Area
    • 5.2.5. By Potency
    • 5.2.6. By Country
      • 5.2.6.1. United States
      • 5.2.6.1.1. By API
      • 5.2.6.1.2. By Manufacturer
      • 5.2.6.1.3. By Type of Drug
      • 5.2.6.1.4. By Therapeutic Area
      • 5.2.6.1.5. By Potency
      • 5.2.6.2. Canada
      • 5.2.6.2.1. By API
      • 5.2.6.2.2. By Manufacturer
      • 5.2.6.2.3. By Type of Drug
      • 5.2.6.2.4. By Therapeutic Area
      • 5.2.6.2.5. By Potency

6. Europe Active Pharmaceutical Ingredients (API) Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By API
    • 6.2.2. By Manufacturer
    • 6.2.3. By Type of Drug
    • 6.2.4. By Therapeutic Area
    • 6.2.5. By Potency
    • 6.2.6. By Country
      • 6.2.6.1. Germany
      • 6.2.6.1.1. By API
      • 6.2.6.1.2. By Manufacturer
      • 6.2.6.1.3. By Type of Drug
      • 6.2.6.1.4. By Therapeutic Area
      • 6.2.6.1.5. By Potency
      • 6.2.6.2. United Kingdom
      • 6.2.6.2.1. By API
      • 6.2.6.2.2. By Manufacturer
      • 6.2.6.2.3. By Type of Drug
      • 6.2.6.2.4. By Therapeutic Area
      • 6.2.6.2.5. By Potency
      • 6.2.6.3. Italy
      • 6.2.6.3.1. By API
      • 6.2.6.3.2. By Manufacturer
      • 6.2.6.3.3. By Type of Drug
      • 6.2.6.3.4. By Therapeutic Area
      • 6.2.6.3.5. By Potency
      • 6.2.6.4. France
      • 6.2.6.4.1. By API
      • 6.2.6.4.2. By Manufacturer
      • 6.2.6.4.3. By Type of Drug
      • 6.2.6.4.4. By Therapeutic Area
      • 6.2.6.4.5. By Potency
      • 6.2.6.5. Spain
      • 6.2.6.5.1. By API
      • 6.2.6.5.2. By Manufacturer
      • 6.2.6.5.3. By Type of Drug
      • 6.2.6.5.4. By Therapeutic Area
      • 6.2.6.5.5. By Potency
      • 6.2.6.6. Belgium
      • 6.2.6.6.1. By API
      • 6.2.6.6.2. By Manufacturer
      • 6.2.6.6.3. By Type of Drug
      • 6.2.6.6.4. By Therapeutic Area
      • 6.2.6.6.5. By Potency
      • 6.2.6.7. Russia
      • 6.2.6.7.1. By API
      • 6.2.6.7.2. By Manufacturer
      • 6.2.6.7.3. By Type of Drug
      • 6.2.6.7.4. By Therapeutic Area
      • 6.2.6.7.5. By Potency
      • 6.2.6.8. The Netherlands
      • 6.2.6.8.1. By API
      • 6.2.6.8.2. By Manufacturer
      • 6.2.6.8.3. By Type of Drug
      • 6.2.6.8.4. By Therapeutic Area
      • 6.2.6.8.5. By Potency
      • 6.2.6.9. Rest of Europe
      • 6.2.6.9.1. By API
      • 6.2.6.9.2. By Manufacturer
      • 6.2.6.9.3. By Type of Drug
      • 6.2.6.9.4. By Therapeutic Area
      • 6.2.6.9.5. By Potency

7. Asia-Pacific Active Pharmaceutical Ingredients (API) Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By API
    • 7.2.2. By Manufacturer
    • 7.2.3. By Type of Drug
    • 7.2.4. By Therapeutic Area
    • 7.2.5. By Potency
    • 7.2.6. By Country
      • 7.2.6.1. China
      • 7.2.6.1.1. By API
      • 7.2.6.1.2. By Manufacturer
      • 7.2.6.1.3. By Type of Drug
      • 7.2.6.1.4. By Therapeutic Area
      • 7.2.6.1.5. By Potency
      • 7.2.6.2. India
      • 7.2.6.2.1. By API
      • 7.2.6.2.2. By Manufacturer
      • 7.2.6.2.3. By Type of Drug
      • 7.2.6.2.4. By Therapeutic Area
      • 7.2.6.2.5. By Potency
      • 7.2.6.3. Japan
      • 7.2.6.3.1. By API
      • 7.2.6.3.2. By Manufacturer
      • 7.2.6.3.3. By Type of Drug
      • 7.2.6.3.4. By Therapeutic Area
      • 7.2.6.3.5. By Potency
      • 7.2.6.4. South Korea
      • 7.2.6.4.1. By API
      • 7.2.6.4.2. By Manufacturer
      • 7.2.6.4.3. By Type of Drug
      • 7.2.6.4.4. By Therapeutic Area
      • 7.2.6.4.5. By Potency
      • 7.2.6.5. Australia & New Zealand
      • 7.2.6.5.1. By API
      • 7.2.6.5.2. By Manufacturer
      • 7.2.6.5.3. By Type of Drug
      • 7.2.6.5.4. By Therapeutic Area
      • 7.2.6.5.5. By Potency
      • 7.2.6.6. Indonesia
      • 7.2.6.6.1. By API
      • 7.2.6.6.2. By Manufacturer
      • 7.2.6.6.3. By Type of Drug
      • 7.2.6.6.4. By Therapeutic Area
      • 7.2.6.6.5. By Potency
      • 7.2.6.7. Malaysia
      • 7.2.6.7.1. By API
      • 7.2.6.7.2. By Manufacturer
      • 7.2.6.7.3. By Type of Drug
      • 7.2.6.7.4. By Therapeutic Area
      • 7.2.6.7.5. By Potency
      • 7.2.6.8. Singapore
      • 7.2.6.8.1. By API
      • 7.2.6.8.2. By Manufacturer
      • 7.2.6.8.3. By Type of Drug
      • 7.2.6.8.4. By Therapeutic Area
      • 7.2.6.8.5. By Potency
      • 7.2.6.9. Vietnam
      • 7.2.6.9.1. By API
      • 7.2.6.9.2. By Manufacturer
      • 7.2.6.9.3. By Type of Drug
      • 7.2.6.9.4. By Therapeutic Area
      • 7.2.6.9.5. By Potency
      • 7.2.6.10. Rest of APAC
      • 7.2.6.10.1. By API
      • 7.2.6.10.2. By Manufacturer
      • 7.2.6.10.3. By Type of Drug
      • 7.2.6.10.4. By Therapeutic Area
      • 7.2.6.10.5. By Potency

8. Latin America Active Pharmaceutical Ingredients (API) Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
      • 8.2.1.1. By API
      • 8.2.1.2. By Manufacturer
      • 8.2.1.3. By Type of Drug
      • 8.2.1.4. By Therapeutic Area
      • 8.2.1.5. By Potency
    • 8.2.2. By Country
      • 8.2.2.1. Brazil
      • 8.2.2.1.1. By API
      • 8.2.2.1.2. By Manufacturer
      • 8.2.2.1.3. By Type of Drug
      • 8.2.2.1.4. By Therapeutic Area
      • 8.2.2.1.5. By Potency
      • 8.2.2.2. Mexico
      • 8.2.2.2.1. By API
      • 8.2.2.2.2. By Manufacturer
      • 8.2.2.2.3. By Type of Drug
      • 8.2.2.2.4. By Therapeutic Area
      • 8.2.2.2.5. By Potency
      • 8.2.2.3. Argentina
      • 8.2.2.3.1. By API
      • 8.2.2.3.2. By Manufacturer
      • 8.2.2.3.3. By Type of Drug
      • 8.2.2.3.4. By Therapeutic Area
      • 8.2.2.3.5. By Potency
      • 8.2.2.4. Peru
      • 8.2.2.4.1. By API
      • 8.2.2.4.2. By Manufacturer
      • 8.2.2.4.3. By Type of Drug
      • 8.2.2.4.4. By Therapeutic Area
      • 8.2.2.4.5. By Potency
      • 8.2.2.5. Rest of LATAM
      • 8.2.2.5.1. By API
      • 8.2.2.5.2. By Manufacturer
      • 8.2.2.5.3. By Type of Drug
      • 8.2.2.5.4. By Therapeutic Area
      • 8.2.2.5.5. By Potency

9. Middle East & Africa Active Pharmaceutical Ingredients (API) Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By API
    • 9.2.2. By Manufacturer
    • 9.2.3. By Type of Drug
    • 9.2.4. By Therapeutic Area
    • 9.2.5. By Potency
    • 9.2.6. By Country
      • 9.2.6.1. Saudi Arabia
      • 9.2.6.1.1. By API
      • 9.2.6.1.2. By Manufacturer
      • 9.2.6.1.3. By Type of Drug
      • 9.2.6.1.4. By Therapeutic Area
      • 9.2.6.1.5. By Potency
      • 9.2.6.2. UAE
      • 9.2.6.2.1. By API
      • 9.2.6.2.2. By Manufacturer
      • 9.2.6.2.3. By Type of Drug
      • 9.2.6.2.4. By Therapeutic Area
      • 9.2.6.2.5. By Potency
      • 9.2.6.3. Qatar
      • 9.2.6.3.1. By API
      • 9.2.6.3.2. By Manufacturer
      • 9.2.6.3.3. By Type of Drug
      • 9.2.6.3.4. By Therapeutic Area
      • 9.2.6.3.5. By Potency
      • 9.2.6.4. Kuwait
      • 9.2.6.4.1. By API
      • 9.2.6.4.2. By Manufacturer
      • 9.2.6.4.3. By Type of Drug
      • 9.2.6.4.4. By Therapeutic Area
      • 9.2.6.4.5. By Potency
      • 9.2.6.5. South Africa
      • 9.2.6.5.1. By API
      • 9.2.6.5.2. By Manufacturer
      • 9.2.6.5.3. By Type of Drug
      • 9.2.6.5.4. By Therapeutic Area
      • 9.2.6.5.5. By Potency
      • 9.2.6.6. Nigeria
      • 9.2.6.6.1. By API
      • 9.2.6.6.2. By Manufacturer
      • 9.2.6.6.3. By Type of Drug
      • 9.2.6.6.4. By Therapeutic Area
      • 9.2.6.6.5. By Potency
      • 9.2.6.7. Algeria
      • 9.2.6.7.1. By API
      • 9.2.6.7.2. By Manufacturer
      • 9.2.6.7.3. By Type of Drug
      • 9.2.6.7.4. By Therapeutic Area
      • 9.2.6.7.5. By Potency
      • 9.2.6.8. Rest of MEA
      • 9.2.6.8.1. By API
      • 9.2.6.8.2. By Manufacturer
      • 9.2.6.8.3. By Type of Drug
      • 9.2.6.8.4. By Therapeutic Area
      • 9.2.6.8.5. By Potency

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Active Pharmaceutical Ingredients (API) Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Active Pharmaceutical Ingredients Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Teva Pharmaceutical Industries Ltd
  • 12.2. Pfizer Inc.
  • 12.3. Novartis International AG
  • 12.4. Mylan N.V.
  • 12.5. Aurobindo Pharma Ltd
  • 12.6. Sun Pharmaceutical Industries Ltd
  • 12.7. Boehringer Ingelheim GmbH
  • 12.8. Dr. Reddy's Laboratories Ltd
  • 12.9. Merck & Co., Inc.
  • 12.10. Lonza Group Ltd
  • 12.11. Bristol-Myers Squibb
  • 12.12. GlaxoSmithKline plc
  • 12.13. AbbVie Inc.
  • 12.14. Lupin Limited
  • 12.15. Cipla Ltd
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations